Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
News Release Digital Asset Direct

Biotech Company Pleased With Results Of Early Testing Demonstrating Vaccine Potential For Multiple Sclerosis

Pasithea Therapeutics Corp.

Learn More about Pasithea Therapeutics by gaining access to the latest research report Vaccines that boost the body’s immune system against foreign proteins are different than those that are an inverse vaccine fighting an autoimmune disease. The latest study from Pasithea Therapeutics Corp. (NASDAQ: KTTA) focuses on the latter. Pasithea is a biotechnology company focused on discovering, researching and developing new and effective treatments for psychiatric and neurological disorders. Pasithea recently announced encouraging preclinical results that support the efficacy of a tolerizing DNA vaccine for multiple sclerosis (MS). Based on its experiments conducted with Hooke Laboratories Inc., Pasithea reported that intramuscular injections of the candidate vaccine (PAS002) delayed the onset of paralysis and reduced peak disease severity. Prophylactic administration also reduced the incidence and severity of relapse in the mouse model. According to the National MS Society, nearly 1 million people are living with MS in the United States, which is more than twice the original estimate. “The results of this study show that this technology has the potential to tolerize GlialCAM, a myelin molecule that has molecular similarity to the Epstein Barr virus (EBV) that triggers MS,” Pasithea Chairman and National Academy of Sciences Professor Lawrence Steinman said. Steinman is a globally recognized authority in MS, and his research led to the development of the drug Tysabri, which is approved to treat patients with MS and Crohn's disease. “Remarkably, the piece of GlialCAM protein shared between EBV and white matter in the brain is also found in the pox viruses, including monkeypox,” Steinman said. “Monkeypox is rarely associated with brain inflammation, and this new technology may prove useful for brain inflammation caused by certain viral infections.” GlialCAM Molecules Mimic Epstein Barr Earlier this year, a study in the leading science journal Nature showed that a molecule called GlialCAM found in the brain’s white matter is attacked in MS. GlialCAM shares a component of its protein structure that mimics an identical component of the Epstein Barr virus Nuclear Antigen-1, which plays a critical role in triggering MS. In Pasithea’s proof of concept study, relapsing paralysis was established in a mouse model of relapsing-remitting experimental autoimmune encephalomyelitis (EAE), the standard animal model of MS. In three groups, a proprietary DNA cassette was engineered to encode GlialCAM and injected to block acute disease and its relapse. Pasithea reported that these DNA molecules were designed to protect against paralytic disease by tolerizing the immune system so it would not attack myelin in the brain and spinal cord. The engineered DNA molecule created tolerance and worked as an inverse vaccine. There are currently 15 vaccines actively under development for Epstein-Barr virus, most in preclinical stages. The vaccine is a recombinant vector vaccine that uses the same technology that AstraZeneca plc (NASDAQ: AZN) and Johnson & Johnson (NYSE: JNJ) used in their COVID-19 vaccines. Moderna Inc. (NASDAQ: MRNA), meanwhile, has started testing the vaccine mRNA-1189 in Phase I studies but does not indicate MS, though the company believes it could potentially assist in prevention. Pasithea’s data showed that the engineered DNA plasmids provide a high level of efficacy in reducing disease severity and incidence of relapse when administered prophylactically in the EAE model, a widely used relapsing-remitting model of MS. "Although early stage, we believe these results demonstrate the promise and validity of our tolerizing approach, which is built on recent data on the biological mechanism linking infection with EBV with the development of MS,” Pasithea CEO Dr. Tiago Reis Marques said. “We have filed a provisional patent application, and we will continue to rapidly pursue the PAS002 drug development program.” The study was conducted at Hooke Laboratories, an independent full-service contract research organization with deep experience in the EAE animal model of MS. At future international conferences, Pasithea plans to present its study data, including histology data and plasma inflammatory markers. The company will also submit complete data for peer-review publication. For more information on Pasithea Therapeutics, visit www.pasithea.com. Pasithea Therapeutics Corporation is a biotechnology company focused on the discovery, research and development of new and effective treatments for central nervous system (CNS) disorders. With an experienced team of experts in the fields of neuroscience and psychopharmacology, Pasithea is developing new molecular entities for the treatment of psychiatric and neurological disorders, including Amyotrophic Lateral Sclerosis (ALS) and Multiple Sclerosis (MS). Pasithea addresses the needs of patients currently suffering with mental illness by providing access to IV ketamine infusions both in clinics and in-home settings. This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. Contact Details TraDigital IR- Camille Baptiste camille@tradigitalir.com Company Website https://www.pasithea.com/

October 03, 2022 09:09 AM Eastern Daylight Time

MedMira provides Progress Update

MedMira Inc.

Today, MedMira Inc. (MedMira) (TSXV: MIR) announces the appointment of Dr. Sam Ratnam as MedMira’s Director of Scientific & Regulatory Affairs and provides an update on its regulatory progress in the U.S. market. U.S. Regulatory Update on COVID-19 Products The recent announced recommendation by the U.S. FDA to IVD manufacturers to apply for the traditional regulatory path 510(k) approval outlines the continuous need for quality COVID-19 rapid test. While the Emergency Use Authorisation (EUA) is continuing, the regulators prepare for the future endemic situation and initiate the standard transition protocol for prevailing diseases. In contrary to the EUA application where manufacturer does not require to meet high quality standard, traditional approval process such as the 510(k) requires full compliance with the FDA Quality System Regulation (21 CFR Part 820). It is the most important mandate for all regulators including FDA and Health Canada to approve the highest quality product to serve the public need. Such requirements may include an existing FDA establishment license and the Medical Device Single Audit Program (MDSAP) certification. MedMira’s product lines REVEALCOVID-19 ® and VYRA™ have the data supporting such an application and can provide additional data if such may be required. At the same time, MedMira’s quality system has been certified for the MDSAP and the Company holds both the FDA and Health Canada establishment license for its North-American based facility. The Company continues with its dual strategy to receive the EUA(s) and the 510(k). This enables MedMira and its distributors to offer the highest regulatory approved products when available to market. While MedMira is in the EUA process, the Company is preparing the 510(k) pre-submission. MedMira will provide further updates on both applications when available. U.S. Regulatory Update on Hepatitis C Product The Company has previously announced the intention of seeking FDA approval for its Point of Care Reveal ® Rapid Hepatitis C (HCV) Antibody Test. According to US Centers for Disease Control and Prevention (CDC), the incidence rate of acute hepatitis C in 2020 has more than doubled since 2013, a 124% increase. MedMira has taken immediate steps and a Q-submission (Q220148) was made to FDA and has received positive feedback. The submitted clinical and non-clinical protocols have been reviewed, and the Company has received clear instructions towards obtaining approval for this greatly demanded product in the USA and other parts of the world. Growth of Scientific and Regulatory Support MedMira has eight regulatory applications pending and is aiming to add three additional regulatory submission in the coming months to our three key markets. Therefore, the management has appointed Dr. Sam Ratnam as Director Scientific & Regulatory Affairs to support MedMira in its growth by introducing more products into the North-American and European markets. Dr. Ratnam brings over 40 years of experience in public health, regulatory affairs and has been the principal in a number of important regulations set forward by the health authorities such as the guidelines on Syphilis, Hepatitis C and HPV. His invaluable expertise and intrinsic knowledge of the regulatory and clinical trial framework in Canada and the United States, will provide the Company even further momentum to push forward on its current and future applications. Trademark REVEALCOVID-19 ® MedMira is delighted to announce the receipt of the United States of America Trademark for its REVEALCOVID-19 brand. The trademark complements the MedMira’s portfolio of trademarked brands and further strengthen its uniqueness. Additional trademarks are currently in the final process which includes VYRA™ (Virus based antigen tests), BYRA™ (Bacteria based antigen/antibody tests) and PYRA™ (Parasite based antigen/antibody tests). About Dr. Sam Ratnam Dr. Sam Ratnam, MSc (Medical Microbiology; Madras), PhD (Medical Microbiology; Delhi), MPH (Johns Hopkins), FCCM (Fellow of Canadian College of Microbiologists), is Clinical Professor at Memorial University, St. John's, and Adjunct Professor, McGill University, Montreal, Canada. He was Director of Public Health Laboratory, Government of Newfoundland, St. John's, and served as Advisor to the National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, and Interim Advisor to the Public Health Laboratory, St. John's. He has served as chair or member of many Canadian federal and provincial advisory committees and working groups and as temporary advisor to the WHO. His research interests are clinical and public health microbiology with focus on STI diagnostics (200 scientific articles and abstracts). Next Updates MedMira will provide further updates on its CE and Health Canada progress in a separate announcement. About MedMira MedMira is a leading developer and manufacturer of Rapid Vertical Flow® diagnostics. The Company’s tests provide hospitals, labs, clinics and individuals with instant disease diagnosis, such as HIV, Syphilis, Hepatitis, and SARS-CoV-2, in just three easy steps. The Company’s tests are sold globally under the REVEAL®, REVEALCOVID-19®, Multiplo® and Miriad® brands. Based on its patented Rapid Vertical Flow® Technology, MedMira’s rapid HIV test is the only one in the world to achieve regulatory approvals in Canada, the United States, China and the European Union. MedMira’s corporate offices and manufacturing facilities are located in Halifax, Nova Scotia, Canada. For more information visit medmira.com. Follow us on Twitter and LinkedIn. This news release contains forward‐looking statements, which involve risk and uncertainties and reflect the Company’s current expectation regarding future events, including statements regarding possible regulatory approval, product launch, future growth, and new business opportunities. Actual events could materially differ from those projected herein and depend on a number of factors including, but not limited to, changing market conditions, successful and timely completion of clinical studies, uncertainties related to the regulatory approval process, establishment of corporate alliances and other risks detailed from time to time in the company quarterly filings. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. Contact Details MedMira Inc. Markus Meile ir@medmira.com Company Website https://medmira.com

October 03, 2022 07:04 AM Eastern Daylight Time

Understanding Inherited Cancer Risk and Genetic Testing

YourUpdateTV

For certain cancers that disproportionally or exclusively affect women, like breast and ovarian cancer, there is a bias to focus on the mother’s side of the family tree in health conversations. And for many, especially previvors – people living at risk of a particular disease but not yet diagnosed – that seemed like enough. But as research has evolved and our understanding of inherited risk has deepened, it has become clearer that genetic risk on our dad’s side of the family can also increase an individual's breast and ovarian cancer risk. Recently, Cancer Previvor Jen Culton and Board-Certified Physician Assistant, Skyler Jesz, participated in a nationwide satellite media tour to discuss inherited risk from dad’s side of the family and some tips to help you take a proactive approach to your health. A video accompanying this announcement is available at: https://youtu.be/0cFRDhC4JHs A recent survey from Myriad Genetics,, a leader in genetic testing, underscores that dad’s side of the family is often overlooked, and much more: More than a third of women do not feel knowledgeable about their father's side of the family. Only 30% of women are very comfortable speaking with their father about their potential risk of getting breast or ovarian cancer, compared to 57% being very comfortable speaking about it with their mother. This is much lower in comparison to the almost 80% of women who consider themselves knowledgeable about their mother’s family health history. 48-year-old Jen Culton sought genetic testing in 2013 after her older sister’s breast cancer diagnosis to find out if she might be at risk. Results showed that she carries a BRCA1 gene mutation and is at increased risk of developing the disease. The news came as a surprise. Jen knew her mother’s health history and it didn’t include cancer. What she didn’t know then: her father’s family history of cancer; the gene mutation came from him. She used this information to take proactive measures to address her risk. For more information, visit myriad.com/knowyourrisk About Jen Culton: Jen Culton is a 48-year-old living previvor. She is at risk for breast and ovarian cancer and came to learn about it in unexpected and surprising ways. It began with her sister Mickey Marasco. Mickey was diagnosed with breast cancer in 2013. Her doctors recommended she undergo genetic testing, and it was discovered that she carries a BRCA1 gene mutation. While undergoing cancer treatment, Mickey had one request: that all six of her siblings undergo genetic testing as well. The siblings went for testing together, and two of Mickey’s sisters (Jen being one of them) were also found to carry the same BRCA1 mutation. For Jen it came as a surprise. She knew her mother’s side did not have a history of cancer. Later she learned that her father’s side did and the gene mutations actually came from their father’s side of the family. But the family’s story doesn’t end there. Jen has three biological daughters – 26, 19, and 10 – who are now facing a similar reality. Genetic testing confirmed that Jen’s oldest daughter is not BRCA1 positive. Her second daughter, however, inherited the BRCA1 mutation from Jen, as well as an ATM gene mutation from her father. Her chances of developing cancer are extraordinarily higher than that of the average woman, up to 87% for breast cancer. With this knowledge, she’s ready to face what’s next, and is considering what proactive measures she should take for her health – just like her mom and her aunts, also BRCA1 positive who sought out proactive measures to manage their risks, and all three are now thriving. About Skyler Jesz, Board Certified Physician Assistant: Skyler Jesz is an Omaha native. She attended the College of Saint Mary, where she earned a Bachelor of Science in Biology. She moved away from Omaha for the first time to attend the physician assistant program at Des Moines University in Des Moines, Iowa. Upon completion of the program, Skyler began her career in the primary care setting, working in a private family practice just outside of Omaha. After more than four years as a primary care provider, she transitioned to her current OBGYN setting. Skyler loves being part of a medical practice that puts patients first and uses the most up-to-date research and recommendations to provide comprehensive and compassionate care. She has a passion for preventative medicine, including genetics and cancer risk assessment. Contact Details YourUpdateTV +1 212-736-2727 yourupdatetv@gmail.com

September 29, 2022 03:46 PM Eastern Daylight Time

Video

Freelancer wins US$6.7m task order with NASA and the National Institutes of Health in gene editing

FREELANCER.COM

Freelancer Limited (ASX: FLN, OTCQX: FLNCF), the world’s largest freelancing and crowdsourcing marketplace by number of users and jobs posted, today announced it has won a US$6.7 million task order for NASA and the National Institutes of Health (NIH) Office of the Director (OD) Division of Program Coordination, Planning, and Strategic Initiatives (DPCPSI) Office of Strategic Coordination (OSC). NIH seeks two, three-phased contests to encourage technology development in two areas of strategic significance as part of Phase II of the NIH Somatic Cell Genome Editing (SCGE) program: A highly efficient (e.g. 50%+ editing efficiency) non-viral delivery system capable of crossing the blood brain barrier to deliver genome editing machinery to a majority of target cell types in the central nervous system. A programmable (e.g. 3+ configurations) delivery system to deliver genome editing machinery that can target specific tissues or cell types. Somatic cell genome editing holds great promise in treating various diseases. However, current techniques in genome editing approaches, such as those based on CRISPR-Cas9, pose many challenges that need to be overcome before they can be widely used in the clinic. For example, the delivery of genome editors to clinically relevant cells and tissues and achievement of editing efficiency that is adequate for addressing human diseases. These contests will be administered under the America COMPETES Act and will be launched on Freelancer.com with a total prize purse of US$6,000,000 (GMV). This is the biggest task order to date under NASA’s NOIS2 and to be selected is testimony to the company’s track record of delivery to date under the program. It is expected that FLN will generate approximately US$700,000 in net revenue contribution for this task order. About the NIH SCGE Program The NIH Common Fund’s Somatic Cell Genome Editing (SCGE) program is working to improve the efficacy and specificity of gene editing approaches to help reduce the burden of common and rare diseases caused by genetic changes. SCGE is developing quality tools to perform and assess effective and safe genome editing in non-reproductive (“somatic”) cells of the body. These research tools will be made widely available to the research community to reduce the time and cost required to develop new therapies. About Freelancer Twelve-time Webby award-winning Freelancer.com is the world’s largest freelancing and crowdsourcing marketplace by total number of users and projects posted. More than 60 million registered users have posted over 20 million projects and contests to date in over 2,000 areas as diverse as website development, logo design, marketing, copywriting, astrophysics, aerospace engineering and manufacturing. Freelancer owns Escrow.com, the leading provider of secure online payments and online transaction management for consumers and businesses on the Internet with over US$6 billion in transactions secured. Freelancer also owns Freightlancer & Loadshift, enterprise freight marketplaces with over 550 million kilometres of freight posted since inception. Freelancer Limited is listed on the Australian Securities Exchange under the ticker ASX:FLN and is quoted on OTCQX Best Market under the ticker FLNCF. End Contact Details Freelancer.com Marko Zitko +61 404 574 830 mzitko@freelancer.com Freelancer.com Sebastian Siseles +1 415-801-2271 sebastian@freelancer.com

September 29, 2022 10:30 AM Eastern Daylight Time

AS&K Group rebrands as Scientific Group

AS&K Group

Leading independent Medical Communications company, AS&K Group, has undergone a rebrand, changing its name to Scientific Group. The move comes a year after the Group celebrated its 25th anniversary and acts to bring its three entities – AS&K Communications, The Corpus and Remedica Communications – under a clear, unified structure, offering a full spectrum of services across a brand’s lifecycle. According to Andrew Ward, Chief Scientific Communications Officer, "Scientific best encapsulates our approach to work – our precision, our creativity and our expertise. We are scientific from the top down." The rebrand also reflects the updated vision for the Group to drive medical communications towards a more sustainable future. “Putting people and the planet first has always been fundamental to the Group. Now our approach is truly at the forefront of the business and highlights what our clients have come to expect when working with us – innovative approaches from the best talent,” said Simon Gee, Chief Creative Officer. Scientific Group was one of the first companies in the medical communications space to join the Science Based Targets initiative (SBTi) and is recognized as a visionary business leader by the United Nations Business Ambition for 1.5°C. About Scientific Group: Scientific Group is an independently owned family of medical communication agencies. Comprising three innovative companies – AS&K Communications, The Corpus and Remedica Communications – Scientific Group offers a full spectrum of services across a brand’s lifecycle for the pharmaceutical, medical device and consumer health sectors. Follow our journey on LinkedIn. #WeAreScientific Contact Details Scientific Group Alana Zdinak alana.zdinak@wearescientific.com Company Website https://wearescientific.com/

September 28, 2022 06:06 AM Eastern Daylight Time

First-of-its-Kind Study Finds Centre for Neuro Skills Patients Show Accelerated Rate of Improvement, Superior Outcomes and Significantly Lower Health Care Costs than Other Patient Journeys

Centre for Neuro Skills

A study * conducted by Optum Advisory Services, a leading information and technology-enabled health services company, found that Centre for Neuro Skills (CNS) patients have dramatically better outcomes and lower health care costs than non-CNS patients. Data was analyzed from 1.2 million patients and 15 million brain injury insurance claims spanning a five-year period starting in 2015. The study compared patients treated at CNS to several other patient journeys including other brain injury rehabilitation service providers, alternate care or home with little or no rehabilitative care. The analyses detailed patient outcomes, hospital readmission rates, emergency room visits and health care costs, including prescriptions. It reviewed “patient journeys,” defined as the care and treatment activities for which insurance claims were submitted. Study highlights include: Average health care cost for CNS patients is 30 percent lower than direct competitors’ patient journeys and 50 percent lower than “other care” or “no care” patient journeys. Average health care costs for CNS patient journeys drops 89 percent in the three years following the first post-injury insurance claim event or “index event.” This is the greatest decline in health care costs of all patient journeys. Among patient journeys with more than $100,000 in therapy costs CNS has the lowest percentage of patients with a hospital readmission, the lowest percentage of patients with an emergency room visit and the greatest prescription cost savings one year after the index event. Key Study Data For more information, please visit: www.neuroskills.com/our-patients/cns-patient-outcomes-2/ Centre for Neuro Skills’ Care-based Founding CEO Dr. Mark Ashley founded CNS in August 1980 to help his brother Steve Ashley, who endured a brain injury at age 21 that left him dependent on others for care. Steve’s journey inspired Dr. Ashley to create CNS. His recovery became the model for CNS’ ongoing philosophy of practice. “When I founded CNS, I wanted to help people with severe brain injury reclaim their lives. I aimed to build a center of excellence for rehabilitative brain injury care. This study proves that we have achieved that,” said Dr. Ashley. “Dramatically superior patient outcomes and health care cost savings relate to CNS’ team of experts’ approach to providing individualized intensive therapies tailored to each person’s injury and needs. Rebuilding life skills and providing comprehensive medical oversite gives patients the foundation for a durable recovery.” Patient Stories: Stroke, Traumatic Brain Injury and Long-haul COVID Since its founding, CNS has helped thousands of patients achieve their goal of maximizing independence and quality of life. Actor and CNS patient Timothy Omundson experienced a massive stroke in 2017 in an airport. Thanks to his intensive therapy with CNS, Timothy started acting again and was even able to walk the red carpet for his role in NBC’s television series, “ This Is Us.” Timothy reprised his recurring role in a new episode of Peacock’s Psych series “ Psych 3: This Is Gus ” late last year. Luke Armstrong, a former CNS patient, sustained a severe traumatic brain injury following a small plane crash in which he was the only survivor. With CNS’ help, one year later, Luke was able to return to school for his senior year of college. Nora Canales is a long-haul COVID survivor who experienced multiple debilitating health and neurological issues. CNS’ rehabilitation program helped her learn to walk again. She has returned home and has become an advocate for COVID safety measures and vaccines. *This study was commissioned by CNS. An Executive Summary can be found here. About Centre for Neuro Skills Centre for Neuro Skills is an experienced and respected world leader in providing intensive rehabilitation and medical programs for those recovering from all types of brain injury. CNS covers a full spectrum of advanced care from residential and assisted living to outpatient/day treatment. Founded by Dr. Mark Ashley in 1980, CNS has seven locations in California and Texas. For more information about Centre for Neuro Skills, visit: www.neuroskills.com, Facebook, Twitter, LinkedIn, YouTube. # # # Media, please note: Visual assets, including photos, are available. To request an interview with CNS leadership or clinical staff, please contact Robin Carr at (415) 971-3991 or CNS@landispr.com. Contact Details Landis Communications Inc. Robin Carr +1 415-971-3991 cns@landispr.com Company Website https://www.neuroskills.com/

September 27, 2022 07:45 AM Pacific Daylight Time

Image

Industrial Defender Appoints Aaron Crow as Chief Technology Officer

Industrial Defender

Industrial Defender, a leader in OT cybersecurity technology, today announced that Aaron Crow has been appointed Chief Technology Officer of Industrial Defender. Crow is a highly regarded industrial cybersecurity expert and brings over two decades of experience in IT and cybersecurity, with more than 15 of those focused on critical infrastructure and power utilities. “Aaron is a talented individual with the right skill set to help propel Industrial Defender into the future and build on our vision to become the global leader in OT cybersecurity solutions,” said Jay Williams, CEO of Industrial Defender, “His vital experience building out security programs and technologies for industrial environments as both an asset owner at a power company and as a consultant is exactly what we need, and I couldn’t be more excited to welcome him to our growing team.” “The world is at a critical juncture right now that will shape how secure our future will be. Industrial Defender is perfectly positioned to be a leader in the global industrial security transformation,” said Crow. “I’m incredibly optimistic about where the company is headed and the role it will play in keeping the technology that powers society safe and operational.” Crow’s impressive background spans operational technology security roles at both Ernst & Young and Luminant, where he built out multiple, large scale OT cybersecurity programs reaching across hundreds of sites, multiple states and different entities. He also holds a Certified Information Systems Security Professional (CISSP®) certification. About Industrial Defender Industrial Defender protects the world’s critical infrastructure from cyberattacks. As a leader in OT cybersecurity innovation, the company’s scalable platform is used by organizations around the world to empower security stakeholders with actionable data from their OT and IIoT infrastructure, enabling them to make informed risk management decisions and manage their OT cybersecurity program in a concise, single vendor dashboard. Learn more at www.industrialdefender.com. Contact Details Erin Anderson +1 617-675-4206 eanderson@industrialdefender.com Company Website https://www.industrialdefender.com

September 27, 2022 09:08 AM Eastern Daylight Time

Elsevier Appoints Emily Singley to the Newly Created role of Vice President, North American Library Relations

Elsevier

Elsevier, a global leader in research publishing and information analytics, is pleased to announce the appointment of Emily Singley to the newly-created role of Vice President, Library Relations, North America. Emily will join Elsevier on October 3, 2022 to strengthen the company’s relationships with the North American library community, and to reinforce Elsevier’s commitment to be a trusted, innovative, and collaborative provider of services and content. She will report to Gwen Evans, Vice President of Global Library Relations, who joined Elsevier in 2020 from OhioLink to lead the company’s engagement and partnerships with the librarian community. Commenting on the appointment, Gwen Evans said: “I am thrilled to welcome Emily to our team at Elsevier. Her invaluable experience, depth of knowledge, and connections within the North American library community will expand our capacity to listen to librarians’ unique concerns and needs to better serve them across the continent.” Emily added: "I am delighted to take on this new role, serving the librarian community that is pivotal to the research endeavor. I’m excited to have the opportunity to listen and learn from academic librarians in North America, and am looking forward to building new, long-lasting partnerships with them.” Emily brings to the role more than 16 years of experience building sustainable partnerships in academic libraries and an expertise in engaging academic leadership in game-changing conversations. She most recently served as Associate University Librarian, Technology and Technical Services at Boston College (BC), an R1 research institution. During her tenure at Boston College, she directed the vision, strategic planning, staffing, and resourcing for five key library programs. In 2022, she successfully engaged with senior university administrators to advocate for significant funding for scholarly communications and Open Access initiatives. Emily’s past positions include Head Librarian, Systems & Applications at Boston College; Systems Librarian at Harvard University; Instructor and Systems/Reference Librarian at Southern New Hampshire University; and Technical Services Supervisor at Curry College. About Elsevier As a global leader in information and analytics, Elsevier helps researchers and healthcare professionals advance science and improve health outcomes for the benefit of society. We do this by facilitating insights and critical decision-making for customers across the global research and health ecosystems. In everything we publish, we uphold the highest standards of quality and integrity. We bring that same rigor to our information analytics solutions for researchers, health professionals, institutions and funders. Elsevier employs 8,700 people worldwide. We have supported the work of our research and health partners for more than 140 years. Growing from our roots in publishing, we offer knowledge and valuable analytics that help our users make breakthroughs and drive societal progress. Digital solutions such as ScienceDirect, Scopus, SciVal, ClinicalKey and Sherpath support strategic research management, R&D performance, clinical decision support, and health education. Researchers and healthcare professionals rely on our over 2,700 digitized journals, including The Lancet and Cell; our over 43,000 eBook titles; and our iconic reference works, such as Gray's Anatomy. With the Elsevier Foundation and our external Inclusion & Diversity Advisory Board, we work in partnership with diverse stakeholders to advance inclusion and diversity in science, research and healthcare in developing countries and around the world. Elsevier is part of RELX, a global provider of information-based analytics and decision tools for professional and business customers. www.elsevier.com. Contact Details Elsevier Andrew Davis andrew.davis@elsevier.com Elsevier Dan DiPietro-James Dan.james@elsevier.com Company Website https://www.elsevier.com/en-xs

September 27, 2022 09:00 AM Eastern Daylight Time

Costly Mistakes to Avoid When Choosing a Medicare Plan

YourUpdateTV

As the next Medicare enrollment period approaches, seniors face a wave of new challenges, including crushing inflation, higher cost of living and impending Medicare changes from the Inflation Reduction Act. Recently, Medicare Expert and Author of new book called It’s Not That Complicated, participated in a nationwide satellite media tour to discuss some costly mistakes that seniors make when choosing a plan and some resources that can help. A video accompanying this announcement is available at: https://youtu.be/5H_g5GihHMA With this extra economic pressure piled on top of the existing complexities of the system, seniors have never needed more help in figuring out how to make the most of their Medicare plan selections. Most seniors say that Medicare is confusing, and many end up in plans that fall short or cost too much. That’s what motivated Ari Parker to write a new book called It’s Not That Complicated. Parker, a Stanford Law School graduate and Medicare expert, has helped thousands of seniors enroll in Medicare as a licensed advisor. In the book, he shares the three Medicare decisions critical to protecting your health and wealth, and the three costliest mistakes seniors make in choosing Medicare plans: 1. Not having access to all plans they’re eligible for 2. Not considering how their individual health needs affects their selection 3. Not understanding how their lifestyle can make certain plans more advantageous For more information on the Annual Enrollment Period and Ari’s book It’s Not That Complicated, visit askchapter.org/ari. People can also call 888-802-1674 to talk with a representative ready to help. About Ari Parker: Ari Parker is one of the country’s leading Medicare experts. He has helped thousands of Americans sign up for Medicare by breaking it down into simple, bite-sized pieces. Ari’s work has been featured in Forbes, CNBC, CBS Moneywatch, MarketWatch, Huffington Post, and many other publications. A graduate of Stanford Law School, he trains and leads Chapter’s team of 30+ licensed Medicare advisors. He lives with his wife and two dogs in Phoenix, Arizona. His book "It's Not That Complicated: The Three Medicare Decisions to Protect Your Health & Money" was released in mid-September. Contact Details YourUpdateTV +1 212-736-2727 yourupdatetv@gmail.com

September 26, 2022 02:35 PM Eastern Daylight Time

Video

1 ... 154 155 156 157 158 ... 227